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Abstract 
The threat of antimicrobial resistance has placed increasing emphasis on the development of 
innovative approaches to eradicate multi-drug resistant pathogens. Biofilm forming 
microorganisms, for example Staphylococcus epidermidis and Staphylococcus aureus, are 
responsible for increased incidence of biomaterial infection, extended hospital stays and 
patient morbidity and mortality. This paper highlights the potential of ultrashort tetra-peptide 
conjugated to hydrophobic cinnamic acid derivatives. These peptidomimetic molecules 
demonstrate selective and highly potent activity against resistant biofilm forms of the Gram-
positive medical device related pathogens. 3-(4-hydroxphenylpropionic)-Orn-Orn-Trp-Trp-
NH2 displays particular promise with minimum biofilm eradication concentration (MBEC) 
values of 125µg/mL against methicillin sensitive (ATCC 29213) and resistant (ATCC 43300) 
S. aureus and activity shown against biofilm forms of Escherichia coli (MBEC: 1000µg/mL). 
Kill kinetics confirms complete eradication of established 24 hour biofilms at MBEC with 6 
hours exposure. Reduced cell cytotoxicity, relative to Gram-positive pathogens, was proven 
via tissue culture (HaCaT) and a haemolysis assays (equine erythrocytes).  
Existing as in nature as part of the immune response, antimicrobial peptides display great 
promise for exploitation by the pharmaceutical industry in order to increase the library of 
available therapeutic molecules. Ultrashort variants are particularly promising for translation 
as clinical therapeutics as they are more cost-effective, easier to synthesise and can be 
tailored to specific functional  requirements based on the primary sequence allowing factors 
such as spectrum of activity to be varied. 
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Introduction  
Increasing resistance to current antimicrobials is one of the most pressing issues impacting 
society. Resistant infections are responsible for high rates of morbidity and mortality, causing 
significant suffering to patients, their family and carers. As resistance to antimicrobials 
increases so too does the possibility of an age were procedures such as joint replacements, 
caesarean sections, chemotherapy, implants and transplant surgery are not possible and 
simple infections kill. Medical devices have an increasingly important role in patient care. An 
estimated 5 million medical devices, for example catheters and hip replacements, are 
implanted each year in the United States [1]. This is due to an increasingly elderly population 
within modern society and a greater demand for technologies to replace the normal 
physiological functions of the human body.. The medical device provides an optimal surface 
for the formation of microbial biofilm. This protective biofilm matrix results in an infection 
10-1000 times more resistant to standard chemotherapy often resulting in failure of both 
device and antimicrobial therapy, leading to removal of the implant. As concerns regarding 
resistance increase there is an urgent need for new antimicrobials that are active against an 
increasing spectrum of pathogens resistant to commonly used therapeutic regimens.  
 
One potential source of novel antimicrobials may be in nature itself with a recent increase in 
focus on traditional therapies to aid chronic and acute disease states. Included in these range 
of remedies are essential oils; traditional remedies for relief of the common cold, acute 
sinusitis and respiratory tract infections. Research by Ioannou demonstrated oils from 
cinnamon bark to be amongst the most microbicidal naturally occurring compounds [2]. 
Antimicrobial peptides serve as an alternative source of therapeutics. A diverse reservoir of 
peptides exist in nature with potent activity shown against a broad range of microorganisms 
via multiple modes of action [3]. Further research has allowed the identification of a 
structural pharmacophore (two units of hydrophobic bulk and two of charge) that acts as the 
minimum motif to provide antimicrobial action [4]. Recently, Bisht et al produced a series of 
amino terminal modified peptides containing two ornithine (providing charge) and two 
tryptophan residues (providing bulk) with significantly reduced minimum inhibitory 
concentration (MIC) values for amino terminal peptides in comparison to C-terminal 
carboxylic acids [5]. This original research paper outlines the activity of a range of ultrashort 
cinnamic acid peptide derivatives against a variety of clinically relevant biofilm forms of 
pathogens implicated in medical device related infection. Their cytotoxicity is compared via 
tissue culture (HaCaT) and haemolysis assays. 
 
Materials and Methods 
Peptide synthesis 
Cinnamic acid, 3,5-dimethoxy-4-hydroxycinnamic acid, 3-(4-hydroxphenylpropionic) acid, 
p-anisic acid and 6-maleimidocaproic acid were obtained from Sigma-Aldrich (Dorset, UK). 
9-fluorenylmethoxy carbonyl (Fmoc) L-amino acids, Rink amide 4-(2’,4’-dimethoxyphenyl-
Fmoc-aminomethyl)-phenoxyacetamido-MHBA (MHBA) resin and 2-(1H-benzotriazole-1-
yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) were obtained from Merck 
Chemicals Ltd (Nottingham, UK). All other reagents were peptide synthesis grade. Peptides 
were synthesised via standard Fmoc solid phase protocols using a CEM Liberty microwave 
enhanced automated peptide synthesiser (1 mmol scale) and are outlined in Figure 1. Peptides 
were cleaved from the resin by a mixture of 95% trifluroacetic acid (TFA), 2.5% 
trisopropylsilane and 2.5% thioanisole (2 hours, room temperature). The identity of each 
peptide was confirmed via mass spectroscopy (Finnigan LCQ Ion Trap Mass Spectrometer). 
Peptide purity was analysed via reverse-phase HPLC using an Agilent 1260 Infinity system, 
fitted with a Gemini C18, 250 mm × 4.6 mm column, a 2−60% acetonitrile gradient [30 min] 
in 0.05% TFA water at a flow rate of 1.5 mL/min. All peptides were found to have >90% 
purity. 
 
Microorganisms, strains and culture conditions 
Biofilm forming medical device related pathogens tested were as follows: methicillin 
resistant S. epidermidis (MRSE) (ATCC 35984), methicillin sensitive S. aureus (ATCC 
29213), methicillin resistant S. aureus (MRSA) (ATCC 43300), E. coli (NCTC 8196) and 
Candida tropicalis (NCTC 7393). Microorganisms were subcultured in Müeller–Hinton broth 
(MHB) prior to testing. 
 
Determination of MIC, minimum bactericidal (MBC)/fungicidal concentration (MFC) 
Broth microdilution tests were performed according to CLS guidelines as described 
previously by our group in 96-well microtitre plates [6]. Peptides were dissolved in MHB and 
sterility ensured by passing through a 0.22µm sterile filter. Peptides were tested over the 
concentration range 1000-3.91µg/mL with MIC determined visually after 24 hour incubation 
at 37ºC. MBC/MFC were determined by inoculating Müeller–Hinton agar (MHA) plates with 
wells that demonstrated inhibited growth (clear wells). Plates were incubated at 37ºC for 24 
hour and observed for 99.9% kill.  
 
Planktonic kill kinetics 
The ability of peptides to kill planktonic isolates were evaluated as previously outlined [7]. A 
concentration of four times the MIC for each peptide allowed for effective analysis of the kill 
kinetics of each antimicrobial. Time points selected to assess planktonic kill kinetics were 10 
minutes (0.1667 hours), 1, 1.5, 2, 4, 6 and 24 hours and five replicates studied. 20µL aliquots 
were removed at each time point and serially diluted in universal neutraliser [7]. Viable 
colony counts, recorded as colony forming units per millitre (CFU/mL), were obtained by 
Miles and Misra technique via plating on MHA and incubating for 24 hours at 37ºC.   
 
Minimum Biofilm Eradication Concentration (MBEC) determination 
The ability of each peptide to eradicate established 24 hour single special biofilms was 
assessed using the Calgary Biofilm Device (MBEC Assay for Physiology & Genetics (P&G), 
Innovotech Inc., Alberta, Canada) by a method developed fully and previously described by 
our group [6].  Biofilms were challenged with each individual peptide (1000-3.91µg/mL) for 
24 hours with six replicates at each concentration. After treatment a recovery plate was 
formed by addition of 200µL of MHB to each well of a separate 96-well microtitre plate and 
incubating the treated MBEC lid (containing pegs) for 24 hours. The plate was examined 
visually and the lowest concentration with no visual growth for each peptide was designated 
as the MBEC.  
 
Biofilm kill kinetics 
Biofilm eradication was evaluated over 24 hours using a Calgary Biofilm Device and a 
method developed previously by our group [7].  If deemed active (MBEC ≤1000µg/mL) 
established 24 hour biofilms of each susceptible microorganism (single species) were 
challenged with the MBEC of each peptide. Peptides deemed non-active (MBEC 
>1000µg/mL) and outside the tested concentration range, were not tested for biofilm 
eradication kinetics. Cinnamic-Orn-Orn-Trp-Trp-NH2, 3,5-dimethoxy-4-hydroxycinnamic-
Orn-Orn-Trp-Trp-NH2, p-anisic-Orn-Orn-Trp-Trp-NH2 and 6-maleimidocaproic-Orn-Orn-
Trp-Trp-NH2 had MBEC values greater than 1000µg/mL (Table 1) against Pseudomonas 
aeruginosa (PAO1), E. coli (NCTC 8196) and C. tropicalis (NCTC 7393) and therefore were 
not tested for biofilm eradication kinetics.  The same is true for 3-(4-hydroxphenylpropionic)-
Orn-Orn-Trp-Trp-NH2 against P. aeruginosa (PAO1). Time points selected for assessment 
were 0.5, 1, 1.5, 2, 3, 4, 6 and 24 hours. At the designated time-points five pegs were 
removed from the Calgary Biofilm Device using sterile flamed pliers and placed into separate 
wells of a dilution plate containing universal neutraliser. Negative controls at each timepoint 
(five replicates) were represented by Phosphate Buffered Saline (PBS) only. Viable colony 
counts (CFU/mL) were obtained for each time-point by serial dilution and plating on MHA 
(Miles and Misra, 24 hour incubation, 37ºC). 
 
Cell cytotoxicity 
HaCaT cell lines (collection number: 400693) were purchased from Cell Line Services 
(Eppelheim, Germany), cultured in Dulbecco's Modified Eagle's Medium (DMEM) 
containing 4500 mg/L D-glucose from Invitrogen (Paisley, UK) supplemented with 2 mM L-
glutamine foetal bovine serum and 1 % penicillin/streptomycin. Cells were grown at 37 ºC/5 
% CO2 and subcultured until 90 % confluency. Cell viability was assessed quantitatively via 
a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay as previously 
outlined [6]. HaCaT cells were cultured until at third passage and inoculated (1x104 
cells/well) into 96-well microtitre plates at 37°C/5% CO2 for 24 ± 1hour, until approximately 
90% confluency. Media was removed and replaced with fresh growth medium (excluding 
penicillin/streptomycin) containing doubling dilutions of each peptide in the concentration 
range 1000 to 3.91µg/ml. Cells were tested for 24 ± 1 hour, after which 10µg/ml sterile MTT 
reagent was added to each well (sterility ensured by passing through 20µM filter). Cells were 
incubated for 24 hours at 37°C/5% CO2, culture medium was removed, and insoluble 
intracellular formazan crystals dissolved with 200µL dimethyl sulfoxide. Absorption was 
measured spectrophotometrically at 570 nm using a Tecan Sunrise® plate reader. Cells 
treated with 70% ethanol represented positive kill controls (0% viability) and PBS acted as a 
negative control (100% viability). Percentage cell viability was calculated relative to 
untreated control wells, taking into account subtraction of the blank value corresponding to 
untreated cells (MTT absent). Results are reported as the mean of six replicates.   
 
Haemolysis assay 
Peptides were assayed for their ability to induce haemoglobin release from fresh equine 
erythrocytes as previously outlined [6]. Fresh defibrinated equine erythrocytes (Laboratory 
Supplies & Instruments Ltd., Antrim, UK) were washed three times with equal volumes of 
PBS and centrifuged for 15 minutes at 900g. Erythrocytes were resuspended 4% 
(volume/volume) in PBS and 100µL of erythrocyte suspension added to each well of a 96-
well microtitre plate. Erythrocytes were exposed to doubling dilutions of peptide (1000-
3.91µg/mL), incubated at 37°C for 1 hour and centrifuged at 1000g. Supernatants were 
transferred to a fresh 96-well microtitre plate, and haemoglobin release determined at 405 nm 
using a Tecan Sunrise® plate reader. Erythrocytes treated with 0.1% Triton X-100 
represented positive controls (100% haemolysis) and PBS (0% haemolysis) acted as a 
negative control. Results are reported as the mean of six replicates.   
Percentage haemolysis was calculated as follows in equation 1: %𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 =  (𝐴𝐴𝐴𝐴𝐻𝐻405 𝑝𝑝𝐻𝐻𝑝𝑝𝑝𝑝𝐻𝐻𝑝𝑝𝐻𝐻 𝑝𝑝𝑡𝑡𝐻𝐻𝐻𝐻𝑝𝑝𝐻𝐻𝐻𝐻𝑡𝑡𝑝𝑝) − (𝐴𝐴𝐴𝐴𝐻𝐻405 𝑃𝑃𝑃𝑃𝑃𝑃)(𝐴𝐴𝐴𝐴𝐻𝐻405 0.1%𝑇𝑇𝑡𝑡𝐻𝐻𝑝𝑝𝐻𝐻𝑡𝑡𝑇𝑇 − 100) − (𝐴𝐴𝐴𝐴𝐻𝐻405𝑃𝑃𝑃𝑃𝑃𝑃) 
Equation 1  
 
Statistical Analysis 
Statistical analyses were carried out using GraphPad Prism 6. Rate of biofilm eradication 
(biofilm viable count (Log10 CFU/peg) at each time point) and planktonic rate of kill (Log10 
planktonic viable counts (Log10 CFU/mL)) for each peptide was examined using a Kruskall-
Wallis test, with a Dunn’s post-hoc test used to identify individual differences relative to the 
untreated control (PBS) for each peptide at each timepoint. These tests were also utilised for 
statistical analysis of tissue culture and haemolysis cytotoxicity data whereby percentage 
viability/haemolysis for the peptides employed were also compared to the untreated (PBS) 
control (100% viability/0% haemolysis). Data was shown to be non-normally distributed 
using the Kolmogorov and Smirnov method, therefore validating the selection of the non-
parametric Kruskal−Wallis test. In all cases a probability of p <0.05 denoted significance. 
 
Results and Discussion 
For ultrashort peptide derivatives, antimicrobial activity is clearly influenced by the nature of 
the N-terminal substituent [6]. Activity against the selected planktonic isolates, Gram-
positive S. aureus and Gram-negative P.aeruginosa and E. coli, were consistent with those 
determined by Bisht and colleagues [5]. For example MIC values obtained by Bisht et al 
against S. aureus, P. aeruginosa and E. coli were reported to be 128, 256 and 256 µg/mL 
respectively. Values obtained by our group (Table 1) display similar correlation (125, 250 
and 250µg/mL). Carboxylic acid derivatives of cinnamon extracts were conjugated to the 
amino terminus to provide further bulk (increasing the lipophilic:charge ratio) and increasing 
antimicrobial activity. 
 
Cinnamic acid and its structural derivatives are phenolic acids. They are highly lipophilic, 
possess anti-oxidant effects, act as chelators and free radical scavengers, and demonstrate 
inherent antimicrobial activity [8]. Examples include ethanolic extracts obtained from exotic 
plants, such as Onosma hispidum, which are associated with the herbal treatment of infection 
and burns [9]. The antimicrobial effects of traditional medicines such as the Iranian folk 
medicine propolis have been attributed to phenolic acids, more specifically; 3,4-
dimethoxycinnamic acid [10]. Related compounds have also generated interest as potential 
agents against tuberculosis and its causative microorganism Mycobacterium tuberculosis. 
Cinnamic acid-based derivatives have been proven to inhibit the fatty acid synthase type II 
system of M. tuberculosis, a process essential for the organism’s survival [11]. The 
antibacterial activity of cinnamic acid derivative’s may be due to inhibition of the bacterial 
cell division protein FtsZ. FtsZ is the key protein of the contractile ring that forms between at 
the bacterial membrane before cell division and cinnamic acid inhibits bacterial replication by 
prevention of its assembly [12]. Truchado et al hypothesised that honey containing hydroxy 
cinnamic acid (similar to 3-(4-hydroxphenyl)propionic acid) may exert its antibacterial action 
by inhibition of quorum sensing pathways [13]. These compounds may therefore provide 
benefit in preventing biofilm formation in both Gram-positive and negative bacteria via 
inhibition of oligopeptides and acylated homoserine lactones respectively, with potential 
benefits for the prevention of medical device related infection.   
 
Cinnamic peptides demonstrate increased selectivity for Gram-positive bacteria MRSE 
(Figure 2), S.aureus (Figure 3) and MRSA (Figure 4). The addition of 3-(4-
hydroxphenyl)propionic acid to the tetrapeptide motif (2HN-Orn-Orn-Trp-Trp-NH2) 
increased anti-biofilm activity against 24 hour established biofilms of Gram-negative E. coli 
and the fungi C. tropicalis (MBEC values: 1000µg/mL, Table 1), with complete eradication 
of the biofilm demonstrated within 24 hours (Figure 5 and 6). Gram-negative bacteria show 
an increased resistance to the antibacterial action of essential oils, in comparison to Gram-
positives due to the presence of an outer membrane consisting of hydrophilic 
polysaccharide chains as a barrier to the mainly hydrophobic character of essential oils [14]. 
The presence of a hydroxy grouping on the 3-(4-hydroxphenyl)propionic moiety (Figure 1, 
structure 3) may allow for increased hydrophilic interaction with outer membrane 
polysaccharides and therefore greater activity against Gram-negative bacteria. The 
importance of this hydroxy grouping in enabling a suitable reduction in the lipohilic:charge 
balance to allow interaction with hydrophilic Gram-negative outer membrane 
polysaccharides is further shown by the activity of 3-(4-hydroxphenylpropionic)-Orn-Orn-
Trp-Trp-NH2 against the planktonic form of P. aeruginosa (MIC, MBC, Table 1).  
 
Related lipophilic moieties provide similar antimicrobial benefits when attached to the 
tetrapeptide motif. 3,5-dimethoxy-4-hydroxycinnamic acid, commonly known as sinapic or 
sinapinic acid, demonstrate antibacterial activity against Gram-negative E.coli due to the 
presence of two methoxyl and one hydroxyl grouping (Figure 1, structure 2) [15]. Such 
groupings have a high affinity for bacterial proteins and specifically enzymes, with the 
presence of at least one phenolic hydroxyl group and a certain degree of lipophilicity shown 
to provide antimicrobial character [16]. Although antimicrobial activity is demonstrated for 
3,5-dimethoxy-4-hydroxycinnamic-Orn-Orn-Trp-Trp-NH2 against planktonic forms of E. coli 
and P. aeruginosa (MIC and MBC values both 250µg/mL for each, Table 1) it is more 
selective for Gram-positive microorganisms, a pattern that correlates to all peptides tested. 
The increased hydrophilicity provided by the two methoxyl and one hydroxyl grouping on 
the 3,5-dimethoxy-4-hydroxycinnamic is negated by the presence of the cationic peptide 
moiety that favours interaction and activity against Gram-positive bacteria and its membrane 
[17]. 
 
Another plant extract containing a methoxy grouping that demonstrates antimicrobial action 
in the literature is p-anisic acid. Originating from sources such as aniseed (Pimpinella 
anisum), p-anisic acid alone displays mg/mL activity against resistant bacterial strains such as 
MRSA [18]. Conjugation to the tetrapeptide motif increases activity of the p-anisic grouping 
further with MIC, MBC and MBEC values at 250µg/mL against MRSA (ATCC 43300). 6-
maleimidocaproic acid was selected as an alternative amino terminal moiety to the cinnamic 
acid derivatives. 6-maleimidocaproic acid is commonly used as a peptide probe for 
identifying thiol groups present within cell membranes, binding with cell membrane bound 
proteins with high affinity [19]. Its ability to increase interactions with microbial membrane 
bound proteins was hypothesised to allow the antimicrobial peptide motif to exert a greater 
antimicrobial action at the membrane interface. The structure of 6-maleimidocaproic acid 
may also provide antimicrobial activity in itself due to the presence of two highly 
electronegative oxygen atoms and a nitrogen supplying charge, balanced by a lipophilic 
hydrocarbon tail (Figure 1, structure 5). However in the majority of cases, the addition of a 
terminal 6-maleimidocaproic grouping to the ornithine and tryptophan containing backbone 
provided no advantage in terms of lowering MIC, MBC or MBEC values when compared to 
results obtained previously with the amino terminal tetrapeptide (H2N-Orn-Orn-Trp-Trp-
NH2) alone [6]. The addition of 6-maleimidocaproic only showed any particular benefit 
against the fungus C. tropicalis with MIC and MFC values halved (MIC: 125 to 62.5 µg/mL, 
MFC: 250 to 125µg/mL) with the presence of an additional lipophilic tail possibly enhancing 
the antifungal action and structure activity relationship of the peptide motif [20].   
 
Kill kinetics were assessed against planktonic microorganisms at four times the MIC value. 
The selection of an antimicrobial concentration of four times the MIC allowed for effective 
analysis of the kill kinetics (bactericidal). Rapid cidal action was demonstrated for all 
peptides with total kill of planktonic microorganisms within 10 minutes exposure (Table S2). 
These results prove a rapid bactericidal effect is achieved within minutes against planktonic 
forms of Gram-positive and negative bacteria and also fungi, likely due to targeting of 
cellular membranes [21]. The mechanism of action of these cationic peptides is mainly due to 
cidal not inhibitory action. The potential for resistance developing is lessened further by 
many antimicrobial peptides possessing similar MIC and MBC values [22]. Many of the MIC 
and MBC values obtained (Table 1) correlate or are within one dilution of each other. For 
Gram-positive microorganisms MBEC values often compare to MIC and MBC values. This 
indicates that these antimicrobial peptides are highly effective with eradication of the biofilm 
matrix and planktonic cells occurring at similarly low concentrations. The peptides tested 
possessed rapid kill kinetics (all within 6 hours) at MBEC values against mature 24 hour 
biofilms of the Gram-positive bacteria MRSE (ATCC 35984), S. aureus (ATCC 29213) and 
MRSA (ATCC 43300). Such rapid kill is indicative of the ability of these peptides to break 
down the extracellular polysaccharide matrix of staphylococci and in particular 
exopolysaccharide intercellular adhesion, that has been shown to increase the resistance of S. 
epidermidis to other antimicrobial peptides including human β-defensin 3, LL-37, and 
anionic dermcidin [23].  
 
Antimicrobial potency shows a marked reduction against biofilms of Gram-negative bacteria 
and the fungus C. tropicalis. Reduced activity against biofilm forms of Gram-negative 
bacteria has also been demonstrated by Chan and colleagues [24]. They observed that 
cationic antimicrobial peptides, over a specific hydrophobicity threshold aided by the 
presence of tryptophan and basic lysine residues, bound to alginate, the main 
exopolysaccharide matrix substance of P. aeruginosa. Binding occurred to such an extent that 
the hydrophilic alginate polymer behaves as an “auxiliary membrane” protecting the biofilm 
bacteria from the action of cationic peptides. The biofilm form of the strain of P. aeruginosa 
(PAO1) utilised in this study is non-mucoid and thus observations of the extracellular 
polymeric substances present in P. aeruginosa (PAO1) show that the main carbohydrate 
constituents are glucose, mannose and rhamnose not the alginic acid components 
mannuronate or guluronate [25]. Therefore other resistance mechanisms must exist to explain 
the relative large increase in MIC, MBC and MBEC values obtained in Table 1. Gram-
negative bacteria have evolved the ability to alter the composition of their outer membrane 
through the modification of lipopolysaccharide molecules [26]. Modification occurs via 
upregulation of the independently acting PhoPQ and PmrAB two-component transduction 
systems resulting in an increased tolerance to cationic antimicrobial peptides and may also 
prevent recognition by the host’s immune response. Research by Mulcahy and colleagues has 
shown extracelluar DNA, a primary constituent of the biofilms of Gram-negative 
microorganisms such as P. aeruginosa, to chelate cations and cationic antimicrobial peptides 
resulting in a 2560-fold increase in resistance to the cationic antimicrobial peptide polymixin 
B [27]. Multidrug resistant pumps are present in many forms of bacteria, particularly Gram-
negatives and fungi, providing a means by which P. aeruginosa, E. coli and C. tropicalis 
could potentially pump antimicrobials out of their cells allowing resistance to develop against 
cationic and conventional antimicrobials, thereby increasing observed MIC, MBC, MFC and 
MBEC values [28]. 
 
Cell toxicity was assessed via a MTT assay using human keratinocyte (HaCaT) cell lines. No 
significant toxicity was demonstrated for any of the peptides up to 1000µg/ml (Figure 7). 
HaCaT cells retained significant viability when treated with modified peptides at all 
concentrations proving they are selective for microbial cells rather than mammalian cells at 
similar concentrations. Cinnamic-Orn-Orn-Trp-Trp-NH2, 3,5-dimethoxy-4-
hydroxycinnamic-Orn-Orn-Trp-Trp-NH2, 3-(4-hydroxphenylpropionic)-Orn-Orn-Trp-Trp-
NH2, p-anisic-Orn-Orn-Trp-Trp-NH2 and 6-maleimidocaproic-Orn-Orn-Trp-Trp-NH2 
demonstrated no significant haemolysis up to concentrations of 1000µg/ml (Figure 8). These 
cationic peptides bind preferentially to the negatively charged phospholipid bilayer of 
bacterial cells [6]. This is advantageous with regard to reducing toxicity in any potential 
therapeutic environment. The structure of human erythrocyte membranes have shown that 
they contain a large number of highly negatively charged sialic acid molecules present in the 
glycocalyx layer as glycosphingolipids and glycoproteins, projecting from the erythrocyte 
surface [29]. These may prove to be potential binding sites for cationic antimicrobials. 
Regardless of this, binding and permeation are much more effective in bacteria than in 
eukaryotic glycocalyx of erythrocytes as peptides find it harder to cross the carbohydrate-
based barrier. The majority of non-haemolytic peptides cannot cross the membrane due to a 
low affinity for the zwitterionic phospholipid bilayer. Cationic antimicrobial peptide’s 
affinity for acidic phospholipids tends to be a lot higher than for zwitterionic phospholipids as 
demonstrated [30]. Selectivity for biofilm forms of Gram-positive bacteria is also greater than 
for eukaryotic cells as demonstrated by complete eradication of biofilms occurring at µg/ml 
concentrations, with no significant cytotoxicity demonstrated within this range.   
 
 
 
Conclusions 
In this paper, we explored the in vitro antimicrobial properties of ultrashort cinnamon-peptide 
hybrids against the more resistant biofilm bacterial phenotype associated with medical device 
infections. The use of ultrashort peptide variants and the attachment of hydrophobic bulk, 
using naturally occurring molecules such as cinnamic acid derivatives, has large potential for 
scale-up and translation by the pharmaceutical industry. This will enable the creation of new 
libraries of effective peptide-based antimicrobial drugs. These molecules compare favourably 
to larger peptides and proteins due to increased ease of synthesis and reduced production 
costs, without compromising function. We found cinnamic acid peptide-based molecules to 
be selective for Gram-positive planktonic and biofilm bacteria and may serve as narrow 
spectrum antibiotics for targeting Gram-positive infections resistant to standardly employed 
antibiotics. 3-(4-hydroxphenylpropionic)-Orn-Orn-Trp-Trp-NH2 demonstrated potent activity 
(1000µg/mL) against Gram-negative bacterial and fungal (C. tropicalis) biofilms and may 
serve as a useful molecule to structurally elucidate and improve activity against these 
problematic pathogens. No significant toxicity was demonstrated using cell culture 
techniques and a haemolysis assay. These results correlate favourably to previous 
toxicological results obtained for cinnamic acid-based compounds. Their therapeutic use, 
particularly in topical/dermatological applications, has been demonstrated to be viable due to 
the widespread use of cinnamic acid in skin products such as perfumes and as ultra-violet 
absorbers in sun creams. The cinnamic acid derivatives have also been shown to provide 
promise in other areas of medicine such as: the treatment of diabetes with stimulation of 
insulin from pancreatic β-cells shown; the stimulation of angiogenesis and healing and anti-
tumour activity. This research demonstrates the high potential for the use of such molecules 
as therapeutics and their potential to be of benefit to limit the increasing spectre of 
antimicrobial resistance, particularly in device related infection. 
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Table 1: The MIC, MBC, MFC and MBEC of cinnamic-Orn-Orn-Trp-Trp-NH2, 3,5-dimethoxy-4-hydroxycinnamic-Orn-Orn-Trp-Trp-NH2, 3-
(4-hydroxphenylpropionic)-Orn-Orn-Trp-Trp-NH2, p-anisic-Orn-Orn-Trp-Trp-NH2, 6-maleimidocaproic-Orn-Orn-Trp-Trp-NH2 against  MRSE 
(ATCC 35984), S. aureus (ATCC 29213), MRSA (ATCC 43300), P. aeruginosa (PAO1) and E. coli (NCTC 8196) 
Peptide 
(all concentrations 
expressed as µg/mL) 
Microorganism 
MRSE (ATCC 
35984) 
S. aureus  
(ATCC 29213) 
MRSA (ATCC 
43300) 
P. aeruginosa 
(PAO1) 
E. coli (NCTC 8196) C. tropicalis (NCTC 
7393) 
MIC  MBC  MBEC  MIC  MBC  MBEC  MIC  MBC  MBEC  MIC  MBC  MBEC  MIC  MBC MBEC  MIC  MFC MBEC  
Cinnamic-Orn-Orn-Trp-
Trp-NH2 
125 125 1000 125 125 500 125 125 1000 125 250 >1000 250 250 >1000 125 125 >1000 
3,5-dimethoxy-4-
hydroxycinnamic-Orn-
Orn-Trp-Trp-NH2 
125 125 500 62.5 125 >1000 250 250 500 250 250 >1000 250 250 >1000 62.5 125 >1000 
3-(4-
hydroxphenylpropionic)-
Orn-Orn-Trp-Trp-NH2 
125 125 125 125 250 250 125 125 125 125 125 >1000 125 125 1000 125 250 1000 
p-anisic-Orn-Orn-Trp-
Trp-NH2 
125 250 250 62.5 125 500 250 250 250 250 250 >1000 500 500 >1000 125 125 >1000 
6-maleimidocaproic-
Orn-Orn-Trp-Trp-NH2 
125 125 125 125 125 125 250 500 500 250 250 >1000 500 1000 >1000 62.5 125 >1000 
 
